Cell Source, Inc.

CLCS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
Assets
Cash & Equivalents $74.6K $22.2K $222.7K $93.1K $241.6K $27.9K $18.9K $371.0K
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets — — — $313.8K $448.8K — — $531.7K
Property, Plant & Equipment — — — — — — — —
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $286.5K $195.2K $409.8K $313.8K $452.3K $114.8K $65.8K $531.7K
Liabilities
Accounts Payable $1.9M $1.5M $680.3K $223.0K $193.1K $135.4K $277.8K $201.8K
Total Current Liabilities — — — $10.1M $8.4M $5.7M $5.0M $5.1M
Long-Term Debt — — — — — — — $50.0K
Total Liabilities $18.8M $15.8M $13.0M $10.1M $8.4M $5.9M $5.0M $5.1M
Stockholders' Equity
Retained Earnings $-46.2M $-41.7M $-36.3M $-31.2M $-25.7M $-21.1M $-16.7M $-14.6M
Total Stockholders' Equity $-18.5M $-15.6M $-12.6M $-9.8M $-7.9M $-5.7M $-4.9M $-4.6M
← Newer Page 1 of 2 Older →